Accessibility StatementSkip Navigation NEW YORK, Sept. 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). Shareholders who purchased shares of LNTH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/lantheus-holdings-inc-loss-submission-f ...

Group 1 - The Rosen Law Firm is reminding purchasers of Lantheus Holdings, Inc. securities from February 26, 2025, to August 5, 2025, about the lead plaintiff deadline on November 10, 2025 [1] - Investors who purchased Lantheus securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that Lantheus provided misleading statements about its product Pylarify's competitive position, failing to disclose critical information regarding pricing and market dynamics [5] - The firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]

Core Viewpoint - The Lantheus Holdings, Inc. class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly concerning its key product, Pylarify, which is used in prostate cancer diagnosis and treatment [4][5][6]. Group 1: Class Action Details - The class action lawsuit is titled Margolis v. Lantheus Holdings, Inc., and covers purchasers of Lantheus securities from February 26, 2025, to August 5, 2025 [1]. - Investors have until November 10, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims that Lantheus's executives created a false impression of the company's financial health and growth prospects [4]. Group 2: Allegations and Financial Impact - The lawsuit alleges that Lantheus reported a year-over-year decrease in Pylarify sales due to a "temporal competitive disruption," leading to a significant reduction in growth projections [5]. - Following the disappointing first quarter results announced on May 7, 2025, Lantheus's stock price fell over 23% [5]. - On August 6, 2025, Lantheus announced further disappointing results, with Pylarify sales down 8.3% year-over-year, causing the stock price to drop nearly 29% [6]. Group 3: Company Overview - Lantheus develops and commercializes diagnostic and therapeutic products for heart disease, cancer, and other conditions, with Pylarify being a key product in its portfolio [3].

Accessibility StatementSkip Navigation NEW YORK, Sept. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lantheus investors who were adversely affected by alleged securities fraud between February 26, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https ...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lantheus investors who were adversely affected by alleged securities fraud between February 26, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/lantheus-holding ...

LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 10, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR LANTHEUS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUIN ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lantheus To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Lantheus between February 26, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Far ...

Accessibility StatementSkip Navigation SAN DIEGO, Sept. 24, 2025 /PRNewswire/ -- Robbins LLPÂ reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Lantheus Holdings, Inc. (NASAQ: LNTH) securities between February 26, 2025 and August 5, 2025. Lantheus is a global company that develops, manufactures, sells, and distributes certain diagnostic and therapeutic products. The Company's key Radiopharmaceutical Oncology product is Pylarify, a PET i ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates inclusive (the “Class Period”), of the important November 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Lantheus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Lantheus and certain ...